If you’ve spent any time on Instagram, a podcast feed, or a wellness newsletter in the last two years, you’ve probably seen the pitch: a 30-minute MRI that scans your entire body for cancer, or a blood draw that tells you your “biological age” is twelve years younger than your driver’s license says. Full-body scanning and longevity medicine have gone from a niche interest for biohacking obsessives to a multi-billion-dollar industry marketed to anyone with a few thousand dollars and a fear of missing something.
Some of that fear is reasonable. Most of the confidence being sold to you is not.
This guide walks through what preventive health scans and longevity clinics actually are, which specific tests have real evidence behind them, which are still unproven, and how to think about the difference — with citations to the primary research throughout, not just marketing copy. We don’t sell scans, and nothing here is sponsored by a provider.
Key takeaways
- “Preventive scanning” is not one thing. Some tests (colorectal cancer screening, coronary calcium scoring for the right patients, DEXA bone density scans) are backed by decades of trial data. Others (general whole-body MRI screening, biological age tests used for individual decisions) are still in early, promising, but unproven territory.
- A 2019 Cochrane review of over 251,000 people found that general “check everything” health checks do not reduce your risk of dying.
- Whole-body MRI screening finds a confirmed cancer in roughly 1 to 1.6 out of every 100 asymptomatic people scanned — and produces far more incidental findings that turn out to be harmless but trigger anxiety and follow-up costs.
- The right question isn’t “should I get scanned?” — it’s “is this specific test, for someone with my age and risk factors, backed by evidence that it changes outcomes?”
What Is Preventive Health Scanning?
Preventive health scanning refers to imaging and lab tests performed on people who have no symptoms, with the goal of catching disease, risk factors, or aging-related decline before they become a problem. It spans a wide range of tools that vary enormously in how well-studied they are:
- Full-body MRI — a scan of most of the body’s soft tissue, marketed mainly for early cancer and aneurysm detection, with no radiation exposure.
- CT-based scoring, like coronary artery calcium (CAC) scans — a low-dose CT that quantifies calcified plaque in the heart’s arteries.
- Low-dose CT lung screening — a targeted scan used specifically in long-term heavy smokers.
- DEXA scans — dual-energy X-ray absorptiometry, used to measure bone density and, increasingly, body composition (fat vs. lean mass).
- Blood biomarker panels — anywhere from a basic metabolic panel to 100+ marker panels covering hormones, inflammation, lipids, and organ function.
- Biological age tests — usually a blood or saliva sample analyzed for DNA methylation patterns (“epigenetic clocks”) that estimate how fast your body is aging relative to your calendar age.
- Genetic and polygenic risk testing — DNA-based estimates of lifetime disease risk.
The critical thing to understand is that these tools are not interchangeable in how well-supported they are. A coronary calcium score and a consumer biological-age test are both “preventive scans” in a marketing sense, but they sit at very different points on the evidence spectrum — which is the whole subject of this article.
What Is a Longevity Clinic?
A longevity clinic is a membership-based medical practice built around comprehensive testing, personalized data, and (usually) an ongoing coaching or physician relationship, with an explicit goal of extending healthspan — the years you spend in good functional health — rather than only treating disease once it appears.
This isn’t entirely new. Longevity clinics are the direct descendants of the executive physical, a category of comprehensive, half-day-or-longer checkups originally built for corporate executives and funded by employers, combining detailed bloodwork, imaging, cardiac evaluation, and risk assessment in a single visit. What’s changed is who it’s marketed to (no longer just executives), what’s bundled in (biological age tests, continuous glucose monitors, epigenetic panels, genetic sequencing), and the pitch (not just “catch problems early” but “extend your lifespan”).
In practice, longevity clinics differ from a standard primary care practice in three ways:
- Scope — far more testing per visit than a standard annual physical.
- Time and access — longer appointments, direct physician or coach access, concierge-style service.
- Framing — optimization and extension of life expectancy, not just disease management.
None of that inherently makes the individual tests offered more or less valid. A longevity clinic can order a coronary calcium scan (strong evidence) and a biological age test used to guide individual treatment decisions (much weaker evidence) in the same visit, under the same premium-priced membership. The clinic’s marketing rarely draws that distinction — which is exactly why it matters.
Where the Evidence Is Strong
Not everything in preventive medicine is hype. Several screening tests have decades of trial data and are recommended by major guideline bodies for specific ages and risk groups — the “if this applies to you, it’s genuinely worth doing” category.
| Test | Who it’s for | Evidence grade | Source |
|---|---|---|---|
| Colorectal cancer screening (colonoscopy, stool-based tests, CT colonography) | Adults 45–75 | Grade A (ages 50–75), Grade B (ages 45–49) | USPSTF |
| Low-dose CT lung screening | Adults 50–80 with a 20+ pack-year smoking history, current smokers or quit within 15 years | Grade B | USPSTF |
| Bone density (DEXA) screening | Women 65 and older | Grade B | USPSTF |
| Coronary artery calcium (CAC) scoring | Adults at intermediate 10-year cardiovascular risk | Supported by 2018 ACC/AHA cholesterol guideline | ACC, 2021 |
Coronary calcium scoring is a particularly good illustration of what “the evidence actually supports” looks like in practice. In the Multi-Ethnic Study of Atherosclerosis (MESA), a long-running NIH-funded cohort study, a CAC score directly quantifies plaque burden in the heart’s arteries and has repeatedly outperformed traditional risk calculators at reclassifying patients’ true cardiovascular risk. Roughly 40% of people classified as “intermediate risk” by standard calculators, but with a CAC score of zero, were reclassified into a lower-risk category — a result with real, guideline-recognized implications for whether someone starts a statin.
Lung cancer screening tells a similarly specific story: the benefit is real, but it’s real for a narrowly defined group — long-term heavy smokers aged 50 to 80 — not for the general population. Applied to the right patients, the USPSTF concluded the benefits (fewer lung cancer deaths) outweigh the harms (false positives, incidental findings, overdiagnosis, radiation exposure). Applied to a 35-year-old nonsmoker looking for “peace of mind,” the same test carries only the harms, with essentially none of the benefit.
That’s the pattern worth internalizing: good evidence in preventive medicine is almost always evidence for a specific test, in a specific population, at a specific interval — not a blanket endorsement of “scanning” as a category.
Curious which of these four apply to you personally? Answer a few quick, non-identifying questions and get personalized eligibility guidance across all 6 categories ScanGlean covers — graded the same way as everything else on this site. Take the Fit Check →
Where the Evidence Is Thin
This is the part the marketing usually leaves out.
Whole-body MRI screening for the general population
The American College of Radiology’s 2023 statement on the subject is unusually blunt for a professional body. It says there “does not believe there is sufficient evidence to justify recommending total body screening for patients with no clinical symptoms,” and that “there is no documented evidence that total body screening is cost-efficient or effective in prolonging life.” Its worry is that these scans turn up “numerous non-specific findings that will not ultimately improve patients’ health but will result in unnecessary follow-up testing and procedures, as well as significant expense.”
The published research backs that caution up with real numbers. A 2019 systematic review in the Journal of Magnetic Resonance Imaging, covering more than 5,300 asymptomatic people across 12 studies, found a pooled rate of 32.1% for critical or indeterminate incidental findings. A good chunk of those “critical” findings turned out to be false positives once doctors looked closer, and almost no studies tracked what happened to people with a clear scan over the long run. A more recent 2025 meta-analysis of over 9,000 asymptomatic people, published in European Radiology, found a pooled confirmed-cancer detection rate of just 1.57%, alongside what the authors called “modest detection rates, frequent incidental findings, unstandardized protocols, and lack of long-term outcome or cost-effectiveness data.”
To put that in plain terms: for every roughly 60–90 people who pay for a whole-body MRI, about one will have a cancer found — and roughly a third will be sent down a path of follow-up scans, biopsies, or specialist visits for something that, most of the time, isn’t cancer at all. The ACR does carve out an exception for genuinely high-risk populations, such as people with Li-Fraumeni syndrome or other hereditary cancer syndromes, where the pre-test probability of disease is high enough to change the math substantially.
Biological age tests, used for individual decisions
Epigenetic clocks are one of the more genuinely interesting developments in aging research, and the population-level science behind them is real. Steve Horvath’s original 2013 clock showed that DNA methylation patterns could estimate age with remarkable accuracy across tissue types. Since then, “second-generation” clocks have gotten better at predicting things that matter: GrimAge, built by researcher Morgan Levine and colleagues specifically to predict lifespan and healthspan, has consistently outperformed earlier clocks at predicting all-cause mortality in cohort studies. DunedinPACE, which grew out of the decades-long Dunedin Study led by Daniel Belsky and colleagues, measures the pace of aging rather than a fixed age, and has since been validated across more than 65 cohorts internationally.
Here’s the catch: all of that validation happened at the population level — comparing group averages across thousands of people over years or decades. Using a single test result to tell one individual person something actionable about their own aging trajectory is a different, much harder problem. A 2025 analysis in Epigenomics put it plainly: “fundamental technical and biological properties” of these algorithms — including sample handling, lab-to-lab variability, and tissue-specific differences in methylation — “prohibit their current use at the individual level.” The authors go further, warning that applying clock results to individual decisions “can be uninformative and potentially harmful.”
In other words: a biological age test can tell a research population something true and useful about aging on average. It’s a much bigger leap for it to tell you something precise enough to justify changing your medications, your supplement stack, or your anxiety level about your own mortality — at least with the current generation of tests.
“Check everything” general health checkups
This isn’t a new question, and it’s already been studied at a scale most people don’t realize. A 2019 Cochrane review — one of the most rigorous forms of evidence synthesis in medicine — pooled 17 randomized controlled trials covering more than 251,000 people to ask a simple question: do general health checks (a mix of questionnaires, exams, blood tests, and screening) reduce your risk of dying? The result: health checks had “little or no effect on total mortality” (risk ratio 1.00), cancer mortality (risk ratio 1.01), or cardiovascular mortality (risk ratio 1.05) — all rated high- or moderate-certainty evidence. The reviewers didn’t hedge: “general health checks are unlikely to be beneficial,” and may lead to unnecessary tests and treatment.
That finding is specifically about unfocused, general checkups — not about the individually targeted, evidence-backed tests listed in the section above. It’s the strongest evidence we have that “more testing” and “better health outcomes” are not the same thing, and it’s a big part of why ScanGlean grades each test on its own evidence rather than treating “comprehensive” as automatically better.
Why “More Data” Doesn’t Always Mean Better Health
None of this is really about people being gullible. The pull toward comprehensive scanning makes a lot of psychological sense, and it’s worth naming honestly.
Loss aversion is stronger than statistics. The fear of missing a treatable cancer looms much larger in most people’s minds than the diffuse, delayed cost of chasing down a false alarm. A scan that finds nothing feels like “proof” of health; a scan you didn’t get feels like an unquantified risk you’re carrying around. That asymmetry is exactly why marketing for these products leans so heavily on stories of scans that caught something, and so lightly on the base rates.
Modern primary care often doesn’t give people room to ask “what about my future risk?” A rushed annual physical, focused on acute complaints, can leave health-conscious people feeling like nobody is looking at the whole picture. Longevity clinics and full-body scans are, in part, a response to that gap — offering time, attention, and a feeling of being taken seriously that a fifteen-minute visit often can’t.
“More information” feels like it can only help. This is the intuition preventive-scan marketing leans on hardest, and it’s the one the research most directly contradicts. Every additional test carries its own false-positive rate, and every false positive can trigger what researchers call a “cascade of care” — a chain of follow-up scans, biopsies, or procedures with its own costs, risks, and psychological toll, often for a finding (an incidentaloma) that would never have caused you a symptom in your lifetime.
That’s the well-documented phenomenon of overdiagnosis: finding a real abnormality that would never have gone on to cause harm, but that you now have to live with, worry about, and possibly treat unnecessarily. Screening only works in your favor when the disease being looked for is both serious and detectable early enough to change the outcome — which is exactly why the evidence-backed tests above are narrow and specific, not broad and universal.
None of this means preventive testing is a bad idea. It means the decision to test is a trade-off with real numbers attached to it, not a costless act of virtue — and that trade-off looks completely different for a coronary calcium score in a 55-year-old with a family history of heart disease than it does for a whole-body MRI in a healthy 30-year-old with no symptoms.
How to Evaluate a Scan or Longevity Clinic Before You Pay
A few concrete questions can cut through most of the marketing:
- What’s the false-positive and incidental-finding rate for this specific test? A credible provider should be able to point you to published numbers, not just testimonials.
- What happens after an abnormal result? Who reads it, who explains it to you, and is a follow-up plan (and its cost) part of what you’re paying for — or a separate bill?
- Is this test recommended for someone with my specific age, sex, and risk factors — or is it being marketed as universally beneficial regardless of who you are?
- Is the protocol standardized? Ask whether the imaging protocol, blood panel methodology, or algorithm has been published or peer-reviewed, or whether it’s proprietary and unverifiable.
- How is the provider paid, and does that affect what they recommend? Affiliate relationships and referral fees aren’t automatically disqualifying, but they should be disclosed.
- Would a clinician recommend this test to someone with your exact profile if you weren’t paying out of pocket for a premium package? If the honest answer is “probably not,” that’s useful information.
The Bottom Line
Preventive health scanning and longevity medicine aren’t a single, monolithic thing to be either fully embraced or dismissed. They’re a toolbox with a few genuinely well-evidenced instruments — colorectal cancer screening, targeted lung cancer screening, coronary calcium scoring in the right patients, DEXA bone density scans for older women — sitting alongside a much larger set of tools, like general whole-body MRI screening and individual biological-age testing, where the science is real, active, and still catching up to the marketing.
The honest version of “should I get scanned?” isn’t yes or no. It’s: which specific test, for someone with your specific risk profile, has evidence that it changes outcomes — and are you clear-eyed about what happens if it finds something that turns out to be nothing? That’s a conversation worth having with a licensed clinician who knows your history, not just a sales page.
This is exactly the kind of question ScanGlean exists to help you answer. We compare providers side by side, grade the evidence behind their claims, and disclose how we make money — because nobody should have to choose between “trust the marketing” and “read fourteen research papers yourself” before spending a few thousand dollars on their own health.
Frequently Asked Questions
What is preventive health scanning?
Preventive health scanning is a category of tests — imaging (full-body MRI, CT calcium scoring, DEXA), blood biomarker panels, and biological age tests — used on people without symptoms to try to catch disease or risk factors early. Some forms, like colorectal cancer screening and coronary calcium scoring in the right patients, have strong evidence behind them. Others, like general whole-body MRI screening, do not yet.
What is a longevity clinic?
A longevity clinic is a membership-based medical practice that bundles extensive lab testing, imaging, and physician or coach access with the goal of extending healthspan (years lived in good health), not just treating existing disease. They differ from a standard doctor’s office mainly in scope, price, and time — not necessarily in the strength of evidence behind every test offered.
Is a full-body MRI worth it?
For the average person with no symptoms or high-risk family history, the evidence is currently thin. A 2025 systematic review found a pooled cancer detection rate of about 1.57% alongside high rates of incidental findings, and the American College of Radiology says there isn’t enough evidence that whole-body MRI screening prolongs life or is cost-effective. It may make more sense for people with a known hereditary cancer syndrome.
Are biological age tests like epigenetic clocks accurate?
At the population level, yes — clocks like GrimAge and DunedinPACE are strong predictors of average mortality and disease risk across large study cohorts. At the individual level, researchers are more cautious: a 2025 analysis in Epigenomics concluded that technical and biological variability currently limit their reliability for personal clinical decisions.
Which preventive scans have the strongest evidence behind them?
Screening tests with strong, guideline-backed evidence include colorectal cancer screening starting at 45, low-dose CT lung cancer screening for long-term heavy smokers aged 50–80, bone density (DEXA) screening for women 65 and older, and coronary artery calcium scoring for adults at intermediate cardiovascular risk. These are recommended for specific ages and risk profiles, not as one-size-fits-all panels.
Do general full-body health checkups reduce the risk of dying?
A 2019 Cochrane review of 17 randomized trials and more than 251,000 participants found that general health checks had little or no effect on all-cause, cancer, or cardiovascular mortality. The reviewers concluded that systematic health checks are unlikely to be beneficial and may lead to unnecessary tests and treatments.
What should I ask before booking a scan or joining a longevity clinic?
Ask what the test’s false-positive and incidental-finding rates are, who reviews and explains the results, what happens next if something abnormal shows up, whether the pricing and methodology are disclosed upfront, and whether the recommendation is backed by a specific guideline or study rather than general marketing language.
This article is for general educational and informational purposes only. It is not medical advice, and it is not a substitute for diagnosis, treatment, or guidance from a licensed physician or other qualified healthcare provider. Always consult a clinician before making decisions about screening, testing, or your health.
Sources
- Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database of Systematic Reviews, 2019.
- American College of Radiology. ACR Statement on Screening Total Body MRI, 2023.
- da Fonseca JM, Trennepohl T, Pinheiro LG, et al. Whole-body MRI for opportunistic cancer detection in asymptomatic individuals: a systematic review and meta-analysis. European Radiology, 2025.
- Kwee RM, Kwee TC. Whole-body MRI for preventive health screening: A systematic review of the literature. Journal of Magnetic Resonance Imaging, 2019;50(5):1489–1503.
- U.S. Preventive Services Task Force. Colorectal Cancer: Screening.
- U.S. Preventive Services Task Force. Lung Cancer: Screening.
- U.S. Preventive Services Task Force. Osteoporosis to Prevent Fractures: Screening.
- American College of Cardiology. New Evidence Supporting Selective Use of Coronary Artery Calcium Scoring for Adults at Borderline 10-Year ASCVD Risk, 2021.
- Horvath S. DNA methylation age of human tissues and cell types. Genome Biology, 2013;14:R115.
- Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY), 2018;10(4):573–591.
- Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife, 2022;11:e73420.
- From population science to the clinic? Limits of epigenetic clocks as personal biomarkers. Epigenomics, 2025.
- Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. Overdiagnosis in primary care research.
- Incidentalomas: managing risks. PMC.